ArticleFrontiers in medicine2026
Case Report: Intravenous transplantation of autologous adipose tissue-derived mesenchymal stem cells attenuated atopic dermatitis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSC) transplantation had been shown to have a potential for reducing chronic pain. MSC transplantation suppresses excessive inflammation, and one of the potential mechanisms of action is a gap junction-meditated reduction of vascular permeability. Herein, we present the case of a 32-year-old female patient who underwent autologous adipose tissue-derived MSC transplantation for chronic pain and showed significant improvement in comorbid atopic dermatitis. Moreover, asthma attacks disappeared after MSC transplantation. This case shows that MSC therapy could be effective for treating allergic diseases, at least in responders. These findings encourage future studies to identify responders, surrogate markers, and the detailed therapeutic mechanisms of MSC transplantation for allergic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.